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Summary 
Autoantibodies have been shown to be present in the circulation of people with 
various forms of solid tumours before cancer-associated antigens can be detected. Un-
like circulating proteins that are shed by bulky tumors, autoantibodies are detectable 
even when antigen expression is minimal and they can be measured up to 5 years pri-
or to disease detection. They are usually directed against oncoproteins, aberrantly ex-
pressed tumour suppression genes, proliferation-associated antigens as well as nuclear 
antigens. 
Existing evidence regarding spontaneous anti-survivin humoral responses in lung 
cancer is inconclusive. Moreover, despite that cancer cell death elicited by radiothera-
py and some chemotherapeutic agents seems to be immunogenic, information about 
the possible effect of treatment on these responses, is lacking. Serum samples from 
33 small cell lung cancer (SCLC) and 117 non-small cell lung cancer (NSCLC) patients 
upon diagnosis, and from 100 controls, were tested by ELISA for anti-survivin antibod-
ies. Cutoff was set to the mean+2SD of controls. 7.7% of NSCLC, none of the SCLC 
patients and 2% of the controls appeared with elevated antibody levels (OR 3.6, 95% 
CI 0.7-17.3 for NSCLC, OR 0.6, 95% CI 0.03-12.6 for SCLC). Measurement of antibod-
ies in 76 NCSLC patients post therapies and  during their follow-up, revealed 12 
NSCLC patients that increased their antibody levels up to 2-38 times, and 7 others 
that decreased them by 2-8 times. No significant correlation was uncovered between 
either the antibody levels upon diagnosis or their changes post therapies and during 
follow-up, and any clinicopathological parameter, their response to treatment and sur-
vival. We conclude that survivin does not induce considerable humoral responses in 
lung cancer. Potentially, however, strong anti-survivin antibody responses can be elic-
ited during the follow-up of the patients, whose clinical significance remains to be elu-
cidated. These findings, together with our previous data concerning survivin expres-
sion and the related cytolytic T cell responses in lung cancer, signify a high tolerogenic 
potential of this tumor-associated antigen. 
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1. INTRODUCTION 
Cancer is a public health problem worldwide. Each year, 6 million people die 
from cancer and 8.1 million new cases are diagnosed. The growth rate of cancer is 
now 2.1% per year, a rate that exceeds that of the world’s population at 1.7 % per 
year. 
Lung cancer was a rare disease at the beginning of the 20th century, but ex-
posures to new etiologic agents and an increasing lifespan, combined to make it a 
scourge of the 20th century. It tends to be more common in developed countries, par-
ticularly in North America and Europe, and less common in developing countries, par-
ticularly in Africa and South America [1, 2]. Lung cancer is the leading cause of cancer 
deaths worldwide; the high mortality associated with this disease is primarily due to 
the fact that the majority of the lung cancers are diagnosed at advanced stages when 
the options for treatment are mostly palliative. 
Lung cancer is one of the most invasive and devastating lung diseases. Based 
on histopathological features, it is divided into two main groups; non small cell lung 
cancer (NSCLC) and small cell lung cancer (SCLC). SCLC and NSCLC cells exhibit dif-
ferences in mutation spectra and hot spots for loss of heterozygosity, which is con-
sistent with the different biological and clinical features of the two lung cancer types 
[3]. Of these two types, NSCLC is the most common (80-85%). NSCLC is further sub-
divided into adenocarcinoma, large cell carcinoma and squamous carcinoma. Adeno-
carcinoma has glandular features and squamous carcinoma shows characteristics of 
epithelial cells. SCLC on the other hand normally expresses properties of neuroendo-
crine cells, characteristics that are not often seen in NSCLC cells and the cells are typi-
cally oat-cell like [3]. 
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1.1. Tumour Immunology 
1.1.1. Cancer development and its microenvironment 
Cancer is characterized by uncontrolled growth and dispersion of cells as a result 
of abnormal changes within the genetic material contained in those cells. A single cell 
or group of cells can undergo genetic events such as mutations, influenced by inherit-
ed or environmental factors in addition to levels of hormones or growth factors, which 
may change the cells’ behavior. These events, which may take years to arise, repre-
sent the process of an oncogenesis. 
When cells divide abnormally during their development, they may evolve into 
immortalized cell population, which may lose the control mechanisms of normal cell 
division, activity and interactions with neighboring cells. Such immortalized cell popu-
lations transform into malignant tumour cell populations, whose behavior can violate 
the tissue environment, by invading and destroying normal tissues. They also metas-
tasize all over the body by releasing tumour cells into the blood and lymphatic system, 
where they continue to grow and develop by forming new cancers. 
 
Figure 1: Schematic of the tumour microenvironment, including tumour cells, endothe-
lial cells, pericytes, fibroblasts, CD4+ and CD8+ lymphocytes and extracellular matrix 
components. 
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Within each foci of tumour, a composite of various cell types can be seen histo-
logical. Apparent from the malignant cells non cancerous cells are also present these 
are usually endothelial cells, pericytes, fibroblasts, inflammatory cells, leucocytes and 
elements of the extracellular matrix (ECM). Collectively, this is known the tumour mi-
croenvironment, as can be seen in (Fig 1). 
This creates a unique microenvironment, which can modify the neoplastic proper-
ties of the tumor cells. The tumor microenvironment is highly dynamic and heteroge-
neous and neoplastic cells have an active cross-talk with stroma and cellular compo-
nents of the inflammatory reaction. Myeloid cells in particular, have a pivotal role in 
coordinating the immune response against a growing cancer [4]. Malignant cells per-
petually stimulate host stromal and vascular cells to conduct physiological invasion. 
Within the same microenvironment, vascular sprouts migrate and invade towards the 
tumour mass while tumour cells migrate outwards in the opposite direction [5]. Activa-
tion of the local invasive environment seems to create a permissive field for the malig-
nant cell [6]. 
Tumour infiltrating lymphocytes (TILs) and their role in the death of tumors has 
long being considered as a positive prognostic indicator of disease progression. TILs 
were defined as “infiltrating lymphocytes” found within the tumor tissues. Ironically, 
the presence of TILs in the context of tumour growth, usually marked recognition of 
the disease and failure of immunosurveillance. The most prominent populations of TILs 
are the CD4+ and CD8+ T cells, the dendritic cell (DC) and macrophages. 
CD8+ cytotoxic T cells (CTL) are the critical effector cells of adaptive immunity 
that actually destroy tumors. They are equipped with specializing cellular mechanisms 
and molecules that cast cell damage. The phenotypic analysis of T cells in human tu-
mors shows that they are memory lymphocytes, although the CD4/CD8 ratio may be 
highly variable from one tumor to another [7]. 
Tumor specific CD4+ and CD8+ T cells act as a “home” to the tumor where they 
participate in the killing of antigen positive tumor cells. CD4+ T cells produce IL-2 that 
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not induces production of IL-15 and also helps to maintain the function and viability of 
the tumor specific CD8+ T cells. Tumor specific CD8+ T cells efficiently recognize their 
tumor targets and induce tumor cell death by both direct and indirect mechanisms. It 
is likely that these CD8+ T cells directly kill many of the tumor cells in vivo. However, 
these cells also produce large amounts of IFN-γ following interaction with their tumor 
targets and thus might also induce tumor cell cytostasis and killing by the IFN-γ de-
pendent mechanisms of cell cycle inhibition, apoptosis and induction of macrophage 
tumoricidal activity [8]. 
Regulatory T cells (Treg) CD4+CD25+ represent a heterogeneous population and 
act on maintaining tolerance and exerting immunosuppression, depending on their rel-
ative number in the CD4+ T-cell pool. The unique feature of Tregs is represented by 
the ability to actively suppress immune responses. The characterization of minor fea-
tures resulted in the classification of Treg into two main subsets: the “naturally aris-
ing” Treg that develop in the thymus due to high-affinity TCR and the “adaptive” Treg. 
The naturally arising Treg triggers and suppresses bystander T-cell proliferation by an 
unknown mechanism requiring cell-to-cell interaction. The adaptive Treg develops pe-
ripherally following antigenic stimulation in the presence of IL-10 (Tr1 subset) or TGF-
β (Th3 subset). In humans, it was observed that T lymphocytes infiltrate non-small cell 
lung cancer and late-stage ovarian cancer expressed CD25 and produced the inhibitory 
cytokine TGF-β, thus suggesting that Tregs were actively hindering anti-tumor immun-
ity [9]. It was later demonstrated that in patients with pancreatic, breast, hepatocellu-
lar and gastric carcinoma, Tregs were expanded not only in the tumor microenviron-
ment but also in the draining lymph nodes, the ascites and the peripheral blood, asso-
ciated with malignancy progression [10, 11]. 
Dendritic cells are the most potent antigen presenting cells (APCs) in the body. 
These cells are efficient at priming naïve T cells because they express high level of 
costimulatory molecules such as B7.1 (CD80), B7.2 (CD86), and CD40 on their sur-
face. In the absence of high levels of costimulatory molecules on APC, a naïve T cell 
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becomes energized upon its first encounter with antigen, thus making the host unre-
sponsive to that particular antigen for life. Several studies have reported that patients 
with large numbers of infiltrating DC within their tumours have better prognosis than 
those with low levels of DC infiltration [12]. Additionally, patients with limited numbers 
of DC infiltrating into tumour site also had an increased incidence of metastases [13]. 
Macrophages (CD45+CD14+) are the major terminally differentiated cells of the 
mononuclear phagocyte system. They are released from bone marrow as immature 
monocytes and circulate in the bloodstream before entering tissues. The ones com-
monly found in human tumors are referred to as tumor-associated macrophages 
(TAMs). Normal macrophages are phagocytic and antigen-presenting cells, which play 
an important role in the control of infections. In contrast, TAMs are re-programmed to 
inhibit lymphocyte functions through release of specific cytokines, prostaglandins or 
reactive oxygen species (ROS). It is hypothesized that re-programming of macrophag-
es occurs in the tumor microenvironment as a result of tumor driven activation [14]. 
Anti-tumor antibodies (Abs) are frequently detected in the circulation of cancer 
patients. It has been assumed that these Abs are made and secreted by plasma cells 
situated in the tumor draining lymph nodes, spleen or other lymphoid tissues. Alt-
hough B lymphocytes (CD19+, CD20+) are uncommon components of human solid 
tumors, plasma cells have been observed in some carcinomas and, occasionally, rep-
resent a substantial infiltrating element [15]. 
Human tumors are sometimes infiltrated by granulocytes, and nests of eosino-
phils may be seen in association with tumor cells in various squamous cell carcinomas, 
for example. By far the most frequent cell in tumors has characteristics of the imma-
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1.1.2. Immune surveillance 
The immune system has three primary roles in the prevention of tumors. First, it 
can protect the host from virus-induced tumors by eliminating or suppressing viral in-
fections. Second, the timely elimination of pathogens and prompt resolution of in-
flammation can prevent the establishment of an inflammatory environment conducive 
to tumorigenesis. Third, the immune system can specifically identify and eliminate tu-
mor cells on the basis of their expression of tumor-specific antigens or molecules in-
duced by cellular stress. The third process is referred to as tumor immune surveil-
lance, whereby the immune system identifies cancerous and/or precancerous cells and 
eliminates them before they can cause harm. The idea that the immune system, which 
so effectively protects the host from microbial pathogens, might also recognize and 
destroy tumor cells was first discussed over a century ago, experimentally approached 
50 years ago and formally demonstrated 10 years ago [16]. Despite tumor immune 
surveillance, tumors do develop in the presence of a functional immune system, and 
therefore the updated concept of tumor immunoediting is a more complete explanation 
for the role of the immune system in tumor development [17]. 
Immunosurveillance is a multivariable process requiring actions of different im-
mune effectors in a manner dependent on the tumor’s cell type of origin, mode of 
transformation, anatomic localization, stromal response, cytokine and chemokine mi-
croenvironment, and the mechanism of immunologic recognition. Thus, it remains crit-
ical to assess the effects of a wide range of immunologic components implicated in 
tumor development in many different models both chemically induced and spontane-
ous, to determine whether the immunosurveillance of all cancer susceptible tissues of 
the body is globally similar or locally distinct. 
However, despite strong evidence supporting the existence of a functional cancer 
immunosurveillance process, immunocompetent individuals still develop cancers that 
are refractory to many treatment approaches. This clinical reality may be explained by 
the failure of the initial host innate and adaptive immune responses to eradicate all the 
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transformed cells. This failure in the face of continued immune pressure favors the 
outgrowth of tumors with reduced immunogenicity. The term ‘‘cancer immunoediting’’ 
has been used to emphasize the dual roles of immunity in both eliminating and shap-
ing neoplastic disease during periods of equilibrium and escape [18]. 
The elimination phase encompasses the original concept of cancer immunosur-
veillance since it represents the most complete form of the immunoediting process 
without progression to the two subsequent phases. It is an ever-ongoing process that 
must be repeated each time the antigenically distinct neoplastic cells arise. For this 
reason, it is particularly noteworthy that cancer is more prevalent in aged populations 
where immune system functions and therefore, cancer immunosurveillance begins to 
decline. 
Although the elimination phase of the cancer immunoediting process can eradi-
cate a significant percentage of transformed cells, there can exist a period of latency 
extending from the end of the elimination phase to the beginning of the escape phase 
and the emergence of clinically detectable malignant disease. This potentially protract-
ed period in the course of the immune system/tumor interaction that occurs prior to 
the detection of clinically apparent tumors constitutes the equilibrium phase. Equilibri-
um is probably the longest of the three phases and may occur over a period of many 
years in humans. 
In the escape phase, some of the tumor cell variants that emerge from the equi-
librium phase develop the capacity to grow in an immunologically intact environment. 
This breach of the host’s immune defenses most likely occurs either when genetic and 
epigenetic changes in the tumor cell confer resistance to immune detection and/or 
elimination, or when the tumor induces a state of immunologic suppression or toler-
ance in the host allowing the tumors to expand and become clinically detectable. Be-
cause both the adaptive and innate compartments of the immune system function in 
the cancer immunosurveillance network, tumors would most likely have to circumvent 
either one or both arms of immunity in order to achieve progressive growth. 
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1.1.3. Tumour Antigens 
Proteins contained within a tumour cell are processed and presented to the im-
mune system as short peptide fragments known as epitopes on major MHC class I and 
MHC class II molecules. The presentation of antigenic epitopes derived from the tumor 
cells allows the immune system to distinguish between normal and transformed cells 
and direct the immune attack based on these antigens. Multiple peptides are pro-
cessed from each protein, allowing several different epitopes or Tumour Associated 
Antigens (TAAs) from tumour-related proteins to be presented on the cell surface [19]. 
Tumour-specific antigens are rare, arising from point mutations, post-translational 
modification or fusion proteins generated by chromosomal translocations [20]. TAAs 
may also be expressed by other normal tissues, but their differential pattern of ex-
pression on tumours allows them to be a target of anti-tumour immunity. Tumor anti-
gens can be classified into five major groups based on their expression patterns (Ta-
ble1). 
Table 1: Tumor antigens based on their expression patterns. 
Antigen Class Antigen Malignancy 
Mutated Antigens 
Immunoglobulin Idiotype, TCR, 
Mutant ras, Mutant p53,  
P21-/bcr-abl fusion 
B & T lymphoma, 
Colorectal, lung, bladder 
Head and neck 
Cancer Testis Anti-
gens 
MAGE-1, MAGE-3, GAGE family, 
20 genes on the X chromosome 
Melanoma, colorectal, lung 
Gastric. 
Viral Antigens Human Papilloma Virus, SBV 





Tyrosinase , gp100 
Prostatic acid phosphates 
Thyroglobulin, α-Fetoprotein 
Melanoma, Prostate, 




CEA, MUC-1, Survivin, hTERT 
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Mutated Antigens 
Mutated antigens are derived from ubiquitous proteins that are mutated in tumor 
cells. Point mutations, chromosomal translocations, deletions, or gene insertions can 
lead to the generation of unique tumor antigens distinct for each tumor. The mutated 
antigens are highly tumor-specific, and some may also be involved in the transfor-
mation process, e.g. Bcr-Abl protein, b-actin. 
Cancer Testis Antigens 
Cancer testis antigens (CTAs), comprise a family of genes that share common 
characteristics: (1) they are expressed in a wide variety of malignant tumors, but ex-
pression in normal tissue is mostly restricted to germ cells of the testis, fetal ovary, 
and placenta, (2) their expression programs are strictly regulated by epigenetic mech-
anisms such as DNA methylation; and (3) they are immunogenic [21]. The prototypi-
cal germ cell antigen, also the first tumor derived (melanoma) human gene product to 
be identified as a CD8+ T cell target, is melanoma antigen-1 (MAGE-1) [22]. More 
than a dozen groups of germ cell antigens have since been identified, including the 
other members of MAGE, GAGE, and BAGE families and this list is growing to include 
NY-ESO-1. 
Over-expressed antigens 
Over-expressed antigens are expressed in a wide variety of normal tissues and 
over expressed in tumors. Genes encoding widely expressed TAA have been detected 
in histologically different types of tumors, as well as in many normal tissues, generally 
with lower expression levels. Among the most interesting TAAs of this group are the 
antiapoptotic proteins (livin, survivin), human telomerase reverse transcriptase 
(hTERT), wild type tumor suppressor proteins p53, epidermal growth factor receptor 
protein  HER-2/neu and MUC1 [23]. 
Tissue-specific differentiation antigens  
Differentiation antigens lack the specificity of tumor-specific shared antigens, as 
they are differentiation markers expressed not just by malignant cells, but also by 
normal cells of a similar origin. Tyrosinase, for example, is expressed by both normal 
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melanocytes and most melanoma cells. Other examples include: gp100, prostatic acid, 
phosphates, Thyroglobulin, α-Fetoprotein. 
Oncogenic Viral Products 
Viral antigens are foreign and are only found on infected cells, making them ideal 
targets due to their high specificity. Although viruses have evolved their own set of 
immune evasion strategies, immunotherapy of virus-associated cancers can be di-
rected against viral-antigens vital for viral replication or growth. The human papilloma 
virus (HPV) E6 and E7 proteins interfere with normal cell-cycle regulation and are re-
quired for the viral life cycle [24 , 25, 26, 27]. 
1.2. Apoptosis in tumors 
In the 1960s, Lockshin and Williams introduced the term “programmed cell death” 
to refer to a gene-directed form of cell death [28]. The term “apoptosis” was coined in 
1972 by Kerr, Wyllie and Currie to describe a form of ischemia induced hepatic cell 
death. The term comes from the Greek (apo + ptosis) for “falling off” and depicts a dis-
tinct morphology of dying cells characterized by cell shrinkage, membrane blebbing, 
chromatin condensation and nuclear fragmentation [29]. 
This gene-directed mechanism by which unnecessary or dangerous cells are trig-
gered to undergo self-destruction does not injure neighboring cells nor does it elicit 
any associated inflammatory response [30]. The core apoptotic pathway was first de-
scribed through genetic analysis in the nematode Caenorhabditis elegans and subse-
quently found in species as diverse as Drosophila melanogaster and humans [31]. The 
dysregulation of apoptosis is intricately involved in the etiology and pathogenesis of 
many diseases including AIDS, autoimmune disorders, neurodegenerative diseases 
and cancer. In general, apoptosis can be divided into the initiation phase, the effector 
phase, and the degradation phase. 
1.2.1. Apoptosis pathways  
There are two pathways that initiate apoptosis: one is the “extrinsic pathway” 
mediated by death receptors on the cell surface; the other is the “intrinsic pathway” 
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involving mitochondria [32]. In a simplified description of the extrinsic pathway, bind-
ing of ligands such as FasL, TNF, or TRAIL to their corresponding receptors (i.e. Fas, 
TNF receptor or TRAIL receptor, respectively) results in the formation of the death in-
duced signaling complex (DISC). The DISC contains the adaptor proteins that allow for 
the recruitment of pro-caspase-8, which leads to its auto-activation. Active caspase-8, 
often referred to as an initiator caspase, subsequently cleaves and activates pro-
caspase-3. Activation of caspase-3, the effector caspase, leads to the ultimate demise 
of the cell (Fig.2) [32]. Alternatively, the intrinsic pathway is triggered by various ex-
tracellular and intracellular stresses, such as growth factor withdrawal, hypoxia and 
DNA damage. These stresses induce a series of biochemical events that result in the 
translocation of a pro-apoptotic Bcl-2 family member into the mitochondria, and the 










Figure 2: The major pathways to apoptosis. Two alternative, but overlapping, path-
ways lead to apoptotic death; the extrinsic pathway acts via death receptors while the 
intrinsic pathway acts via release of mitochondrial proteins. Activation of either path-
way leads to activation of a common executioner pathway. In both pathways, the ex-
trinsic and intrinsic pathways, initiator caspases are activated, CASP 8 (and probably 
10) for the extrinsic pathway and CASP 9 for the intrinsic pathway. The initiated 
caspases active executioner caspases which cleave death substrates, leading to cell 
death. The two major initiator pathways interact via the Bcl-2 family member. 
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1.2.2. Inhibitors of apoptosis proteins (IAPs) 
"Inhibitor of apoptosis proteins" (IAPs), a family of endogenous caspase inhibitors, 
are highly conserved throughout evolution and comprise the human analogues XIAP (X-
linked inhibitor of apoptosis), cIAP1 (cellular IAP1), cIAP2, survivin, apollon and livin 
[33 , 34]. The IAP family of proteins contains three conserved structural motifs, the 
Baculoviral IAP repeat (BIR), RING (RING zinc-finger) and the Caspase Activating and 
Recruitment Domain (CARD) (Fig.3). Classification as an IAP protein requires the 70-80 
amino acid long BIR domain, referring to the original discovery of these protein,  XIAP-
associated factor-1  (XAF-1) has been identified to negatively control IAP activity [35]. 
The second structural motif found within many IAPs, the RING zinc-finger, functions as 
an E3 ubiquitin ligase.  Moreover, the CARD is found within c-IAP1 and c-IAP2, located 
between the three N-terminal BIR domains and the C-terminal RING-finger domain. 
CARD domains are structurally related to death and death effector domains and typical-
ly mediate oligomerization with other CARD-containing proteins. 
IAPs are negatively regulated by caspase-mediated cleavage, processing by the 
serine protease Omi/HtrA2 or by proteasomal degradation, for example through RING 
domain-mediated auto- or heteroubiquitination. In addition, mitochondrial proteins, 
e.g. Smac/DIABLO or Omi/HtrA2, translocate into the cytosol upon induction of apop-
tosis and promote apoptosis through binding and antagonizing. Human IAPs contain 
from one to three copies of the BIR domain and usually, also harbor one or more of 
the other functional domains. Of the mammalian IAP proteins known to be involved in 
apoptosis, XIAP has been characterized most extensively. XIAP contains three BIR 
domains and a C-terminal RING motif. The second and third BIR domains of XIAP are 
potent inhibitors of caspase-3/-7 and caspase-9 respectively, via distinct mechanisms 
[36]. The linker segment preceding the BIR2 domain binds to the active site of effector 
caspase-3 or -7, thereby preventing substrate binding and subsequent catalysis [37 , 
38]. 
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1.3. Survivin  
Survivin is the smallest member of the inhibitor of apoptosis family of pro-
teins (IAPs). It is implicated in the preservation of cell viability, directly inhibiting 
caspase-3 and -7 activity and regulating the cell cycle in G2/M phase [39 , 40]. During 
oncogenesis survivin gene undergoes alternative splicing resulting in the appearance 
of four as yet identified variants [41 , 42]. Amongst them, the function of the survivin-
3B and -2α is not yet elucidated, while survivin-2B seems to be pro-apoptotic, and 
survivin-∆Εx3 appears to function similarly with survivin [43 , 44]. Survivin and its 
variants are rarely expressed in terminally differentiated adult tissues but they appear 
to be highly upregulated in most cancers [40]. Especially in lung cancer, expression 
levels of survivin appear to relate with disease prognosis [45 , 46]. 
Figure 3: Schematic representation of the human inhibitor of apoptosis protein family (IAP).  
Eight human BIR containing proteins, Abbreviations as follows: BIR: Baculovirus IAP repeat; 
XIAP: X-linked IAP, CARD, caspase activation and recruitment domain, RING: Ring zinc-
finger, NBL: nucleotide-binding locus, UBC: ubiquitin-binding complex, NAIP: Neuronal 
apoptosis-inhibitory protein. 
1.3.1 The biology of Survivin 
At 16.5 kDa, survivin is the smallest mammalian member of the IAP gene fami-
ly [47]. Structurally, it contains a single BIR, an approximate 70-amino acid zinc finger 
fold that is the hallmark of all IAPs, and an extended –COOH terminus α-helical coiled-
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coil (Fig.4), but no other identifiable domain  typically found in IAPs [48]. Based on X-
ray crystallography of the human or mouse protein, survivin is a stable homodimer in 
solution with the –COOH terminus α -helices protruding from the core dimer [49, 50, 
51]. A single copy of survivin gene located on chromosome 17q25 (human), or 11E2 
(mouse), gives rise to four alternatively spliced survivin transcripts (Fig.5). In addition 
to wild-type survivin (142 amino acids), four survivin isoforms are generated by inser-
tion of an alternative exon 2 (survivin-2B, 165 amino acids), (survivin-3B, 120 amino 
acid) contains 5 exons including an extra novel exon3B, removal of exon 3 (survivin-
∆Ex-3, 137 amino acids) or acquisition of an in-frame stop codon in intron 2 (survivin-
2a) [52, 53]. In survivin- ∆Ex-3, the splicing event introduces a frame shift that gen-
erates a unique –COOH terminus of potential functional significance [54]. 
A unique property of survivin is a sharp cell cycle-dependent expression at mi-
tosis. This is largely, but not exclusively, controlled at the level of gene transcription 
and involves canonical CDE/CHR boxes in the survivin promoter acting as potential G1- 
repressor elements [55 , 56]. Among the post-translational modifications that affect 
survivin expression levels, interest has recently focused on the control of protein sta-
bility. Survivin is a relatively short lived protein (t1/2 = 30 min), and polyubiquityla-
tion followed by proteasomal destruction has been shown to contribute to cell-cycle 
periodicity by keeping survivin levels low at interphase [57]. In addition, mitotic phos-
phorylation of survivin on Thr34 by p34cdc2– cyclin B1 has been associated with in-
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Figure 4: Ribbon Representation of the Survivin Dimer.  The β strands, α- helices, and 
loops are represented as violet arrows, green coils, and brown lines, respectively. The 
zinc atoms are shown as blue spheres, and black arrows indicate the trypsin cleavage 
sites [59]. (a) The dimer 2-fold axis is in the plane. (b) The view in (a) rotated by 90° 
around the horizontal axis; the 2-fold axis is perpendicular to the plane. 
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Figure 5: Survivin splice variants: The survivin gene is composed of exons1–4. All 
identified survivin isoforms contain exons1 and 2. Survivin-2B has an extra exon2B; 
survivin-deltaEx3 is missing exon 3; survivin-3B contains 5 exons including an extra 
novel exon3B derived from a 165 bp  long portion of intron3; and survivin-2a consists 
of 2 exons(exons1 and 2) as well as a 30 197 bp region of intron 2. 
 
The search for signaling intermediates that control survivin expression has gen-
erated interesting findings. One common denominator of this pathway is the require-
ment for PI3-kinase/Akt activation. This is a general antiapoptotic signal  that has 
been implicated in up-regulation of survivin induced by granulocyte macrophage-
colony stimulating factor (GM-CSF), CSF, Ang-1, and fibronectin-dependent cell adhe-
sion [60, 61 , 62]. In addition, modulation of survivin expression has been observed in 
endothelial cells stimulated with non-mitogenic concentrations of interleukin (IL)-11 
engagement of vascular endothelial (VE)-cadherin expression, and function or angio-
tensin II stimulation [63, 64].  Another critical transcriptional regulator of survivin ex-
pression in pleural effusion lymphoma cell sustained by vascular endothelial growth 
factor (VEGF), IL-6, or IL-10, was identified as activated signal transducers and activa-
tors of transcription (STAT3) [65]. This is potentially important for the known role of 
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STAT3 in cytoprotection, which may have direct consequences for oncogenic transfor-
mation [66, 67] 
1.3.2. The role of survivin in cell division 
Survivin is essential for proper execution of mitosis and cell division [68]. Its 
specific expression in G2/M is transcriptionally controlled as being typical of mitotic 
genes [69]. During mitosis, survivin binds to the micro-tubules of the mitotic spindle 
through its carboxy terminal alpha helices. Interference of survivin-microtubule inter-
actions, by means of an antisense-mediated reduction in the expression of survivin, 
results in a failure of the antiapoptotic function of survivin and an increase in caspase-
3 activity with subsequent apoptosis [70]. Disruption of survivin function has likewise 
been linked with cell division defects exemplified by supernumerary centrosomes, for-
mation of multipolar mitotic spindles, and failure of cytokinesis, with cells becoming 
polyploid and multinucleated. Additional evidence for the crucial role of survivin in mi-
tosis has been demonstrated in knockout mice. Homozygous disruption of the survivin 
gene resulted in embryonic death at 4-5 days, with the null embryos revealing failed 
cytokinesis and disrupted microtubule formation [71]. 
1.3.3. Role of survivin in inhibition of apoptosis 
The question as to whether survivin had also a distinct and separable role in 
apoptosis inhibition similar to other mammalian IAPs or whether its function is limited 
to cell division, as with IAPs in yeast and C. elegans, has been amply investigated in 
recent years [47, 72 , 73] . With the expansion of experimental work on survivin, 
three lines of experimental evidence clearly support the notion that survivin has an 
independent and separable role in apoptosis inhibition, in vitro and in vivo. First, over-
expression of survivin has been associated with inhibition of cell death initiated via the 
extrinsic or intrinsic apoptotic pathways. Second, transgenic expression of survivin re-
sulted in apoptosis inhibition in vivo and livers isolated from heterozygous survivin +/– 
animals exhibited exaggerated apoptosis in response to suboptimal ligation of Fas [74 , 
75]. Third, molecular antagonists of survivin, including antisense, ribozymes, siRNA 
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sequences, or dominant-negative mutants resulted in caspase dependent cell death, 
enhancement of apoptotic stimuli, and anticancer activity, in vivo [76 , 77 , 78 , 79]. 
However the precise mechanism by which survivin suppresses apoptosis is still not well 
understood. Several mechanisms are under consideration (Fig. 6). Direct suppression 
of caspase-3 by survivin has been speculated by some investigators; yet, survivin 
lacks structural components present in other IAPs that allow their direct binding to 
caspase-3.  There is also speculation that survivin binds to caspase-9 but there are 
likewise problems with this theory. Phosphorylation of survivin on the threonine at po-
sition 34 (Thr34) is critical for a functional survivin molecule. However, phosphoryla-
tion of survivin fails to explain why this would promote interaction with caspase-9. 
 
Figure 6: Potential mechanism by which survivin inhibits apoptosis: survivin may in-
hibit apoptosis by binding caspase-9 or it may block Smac, thus preventing this 
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1.3.4. Survivin and cancer 
Strong survivin expression is observed in the vast majority of cancers [80]. 
These include esophageal, lung, ovarian, central nervous system, breast, colorectal, 
bladder, gastric, prostate, pancreatic, laryngeal, uterine, hepatocellular, and renal 
cancers, as well as melanoma and soft tissue sarcomas. Survivin is also highly ex-
pressed in patients with hematologic malignancies including lymphomas, acute leuke-
mias, and myelodysplastic syndromes, which progress to overt leukemia [81]. In can-
cer cells, elevated survivin is commonly associated with enhanced proliferative index, 
reduced levels of apoptosis, resistance to chemotherapy , and increased rate of tumor 
recurrence [82 , 83, 84 ,85]. Retrospective studies evaluated the correlation between 
survivin, disease variables, and clinical outcomes. Elevated survivin expression is as-
sociated with clinicopathologic variables of aggressive disease and shows a strong cor-
relation with shorter disease-free or overall survival in most studies, identifying it as a 
significant independent prognostic indicator of poor outcome in patients with most tu-
mor types. 
1.3.5. Survivin as a target for new anticancer strategies 
Overall, the results obtained by different studies aimed at targeting survivin by 
means of different approaches, demonstrated that inhibition of this cell survival factor: 
(a) promotes spontaneous apoptosis in tumour cells (although this effect was not ob-
served in all studies) and (b) enhances the efficacy of several types of conventional 
treatments including chemotherapy, radiotherapy and immunotherapy. Accordingly 
considerable efforts have been made to validate survivin as a new target in cancer 
therapy. Phase I/II clinical trials of survivin-directed immunotherapy have been con-
ducted in patients with advanced melanoma, pancreatic, colon, and cervical cancer, 
and have shown promising results without significant adverse effects [86, 87]. 
Also several experiments targeting survivin expression are currently under inves-
tigation. For example, a replication-deficient adenovirus encoding a survivin Thr34-Ala 
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(pAd-T34A) mutant to target tumor cells of breast, cervical, prostate, lung, and colo-
rectal cancers causes the tumor cells to undergo apoptosis without affecting prolifera-
tion of normal fibroblasts, endothelium, or smooth muscle cells. The combination of 
pAd-T34A with the chemotherapeutic agent, taxol, results in enhanced tumor cell 
death. Intratumor administration of pAd-T34A in mice in vivo also inhibits tumor 
growth and induces apoptosis. 
Evidence that dysregulation of the survivin pathway leads to apoptosis in cancer 
is also seen in melanoma cell lines transfected with T34A, which interferes with phos-
phorylation of endogenous survivin. This results in spontaneous apoptosis of the mela-
noma cell line and enhanced in vitro cell death by the chemotherapeutic agent cisplatin 
[88]. Finally, down regulation of survivin expression using an antisense oligonucleotide 
within a lung carcinoma cell line induces apoptosis and inhibits growth of the neo-
plastic cells [89]. Furthermore, a synergistic effect was noted when this cell line was 
treated with antisense oligonucleotides and the chemotherapeutic agent, etopside. 
This finding demonstrates that targeting of the survivin pathway in cancer, alone or in 
conjunction with chemotherapeutic agents, has potential as a novel therapeutic regi-
men. 
Immunotherapy appears to be a plausible approach to treating survivin-positive 
tumors; autoantibodies against survivin have been detected in humans with lung and 
colorectal cancer, making this a potential diagnostic tool in certain neoplasms [90]. In 
some of the lung cancer patients, anti-survivin reactivity was discovered before the 
clinical findings. Thus, antibodies against survivin may prove to be an early predictive 
marker of cancer. Spontaneous cytotoxic T lymphocyte responses to survivin, in a ma-
jor histocompatibility complex class I restricted manner, have been detected in pa-
tients with chronic lymphocytic leukemia, melanoma, and breast cancer [91, 92]. In 
addition, in vitro cytolytic T-cell induction against a survivin epitope results in lysis of a 
wide variety of human tumors, including renal cell carcinomas, breast cancer, colon 
cancer, multiple myeloma, and leukemias [93]. Hence, survivin appears to be a uni-
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 05:48:26 EET - 137.108.70.7
Anti-survivin autoantibodies in lung cancer 
Page 29 of 83 
versal tumor antigen and immunotherapy emerges as a conceivable approach to treat-
ing survivin positive tumors. 
1.3.6. Survivin as a therapeutic target for radiation sensitization 
Since survivin is preferentially expressed in malignant cells and is prognostically 
important, it acts as an attractive therapeutic target. Efforts are under way to develop 
survivin inhibitors for clinical use with the dual aim, to inhibit tumor growth through an 
increase in spontaneous apoptosis and to enhance tumor cell response to apoptosis-
inducing agents [93]. 
Different kinds of survivin molecular antagonists, including antisense oligonucleo-
tides, ribozymes, small interfering RNAs (siRNAs), as well as cancer vaccines, have 
been used. The results obtained in a variety of studies indicate survivin to be an im-
portant factor in determining the radiation response of human tumor cells. Due to its 
differential expression in cancerous tissues and its potential requirement for maintain-
ing cancer-cell viability survivin displays a suitable molecular target for radiosensitiza-
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Figure 7: Schematic presentation of the role of survivin as a radioresistance factor 
and molecular target for radiosensitization of tumor cells. (1) Enhanced expression of 
survivin mediates radiation resistance of tumor cells through suppression of apoptosis 
by interfering with caspase activity(2) The antiapoptotic activity of survivin is depend-
ent on a CRM1-mediated pathway of nuclear export, as export-deficient survivin mu-
tants failed to protect tumor cells against radiation-induced apoptosis . (3) Besides its 
role as an inhibitor of apoptosis, survivin also acts as a cell cycle regulatory protein, 
enabling coordinated cellular division. Accordingly, depletion of survivin alters cell cy-
cle distribution, resulting in a G2 and mitotic arrest. (4) In addition, survivin appears 
to be involved in the regulation of DNA repair, thereby enhancing tumor cell survival 
upon radiation exposure. 
Different strategies to counteract survivin’s expression or activation in tumor cells 
have demonstrated that its inhibition results in an increase in spontaneous and radia-
tion-induced apoptosis and thus enhances the response towards cancer treatments in-
cluding chemotherapy and radiotherapy [95 , 96]. These strategies comprise antisense 
oligonucleotides, ribozymes, siRNA and dominant-negative mutation [97 , 98 , 99].  
Due to the fact that CDC2 phosphorylation of survivin is required for cancer- cell via-
bility, the use of kinase inhibitors, including CDC2 antagonists, is another promising 
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approach to enhance the response towards cancer treatments. The radiosensitizing 
activity of survivin inhibition seems to be multifaceted and involves caspase-dependent 
and caspase-independent mechanisms like impaired DNA repair as well as an altered 
cell-cycle distribution, formation of multinucleated cells and mitotic arrest and subse-
quent cell death [100]. 
Overall, the results obtained in the different studies indicate survivin to be a cel-
lular factor potentially involved in the chemo-resistant and radio-resistant phenotypes 
of human tumours cells and suggest that approaches designed to inhibit survivin ex-
pression may lead to human tumour sensitization to chemical and physical agents. 
1.4. Measurement of antibodies against tumour proteins  
It is well demonstrated that cancer is immunogenic, and multiple tumour anti-
gens have been identified in cancer patients. It is now possible to potentially harness 
the immune response elicited by cancer growth as a potential diagnostic tool. Humoral 
immunity, or the development of autoantibodies against tumor-associated proteins, 
may be used as a marker for cancer exposure. Unlike circulating proteins that are shed 
by bulky tumors, serum autoantibodies are detectable even when antigen expression 
is minimal. 
1.4.1. Methods 
An optimal method for detecting cancer-specific antibodies must be defined. The 
two major methods for detection of tumor-specific antibodies are immunoblotting 
(Western blot) and enzyme linked immunosorbent assay (ELISA) systems. Western 
blot analysis involves separating tumor proteins by gel electrophoresis, transferring to 
nitrocellulose, and then probing with patient serum samples. While Western blotting is 
useful for identifying new immuno-genic tumor proteins, it is not a quantitative assay. 
By contrast, ELISA methodology allows a quantitative evaluation of the antibody re-
sponse and is capable of allowing the analysis of a great number of patients with little 
effort. Use of ELISA requires a source of reasonably pure protein for detection of anti-
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bodies. The type of ELISA used to detect antibody responses, such as "sandwich" or 
"indirect" ELISA, may affect the sensitivity of the test.  A "sandwich" ELISA allows an 
impure source of protein to be used. Briefly, the method entails the binding of a pro-
tein-specific monoclonal or polyclonal antibody to the surface of a plate followed by 
incubation with the protein of interest in solution with protein binding to the antibody, 
impurities are washed away, and the antibody-bound protein can then be probed with 
patient sera. An "indirect" ELISA requires a purified source of protein, such as recom-
binant protein or chemically synthesized fragments of protein termed "peptides." The 
pure antigen can be directly bound to the surface of a plate and probed with patient 
sera. 
Besides these two major methods there are other ones like; Immunofluoresence 
assay (IFA) in this test serum is incubated with antigen immobilized on a 96-well plate 
or microscope slide, secondary antibodies labeled with fluorescence are then added. 
After washing, any bound secondary antibodies can be detected by UV light on the 
slide. Moreover, a high-throughput approach to autoantibody discovery is protein array 
as robotic microarray spotters. This allows the grouping of thousands of proteins in 
replicate onto a single glass slide and makes it possible to evaluate the presence of 
serum antibody to hundreds of proteins simultaneously. 
The sensitivity of each approach may differ depending upon experimental condi-
tions, and the ability to develop a successful diagnostic assay. This includes several 
factors such as the ability to detect the autoantibody in the premalignant state, the 
prevalence of the autoantibody in a specific population, or even the specificity of the 
autoantibody for a specific tissue type. Population-based studies of individual autoanti-
bodies can give some indication of whether the detection of humoral immunity may aid 
in discriminating cancer patients from non cancer bearing individuals. It is important to 
explore several strategies with a series of candidate antigens to determine the most 
optimal method to be further developed for use in screening for the presence of cancer 
in a high-risk or asymptomatic population. 
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1.4.2. Antibody response to oncogenic proteins 
The humoral immune (HI) response is mediated by B lymphocytes through the 
production of antibodies. Antibodies can kill tumor cells by different mechanisms: 
• IgG or IgM antibodies fix complement and can destroy soft tumors. 
• Antibodies directed against antigens expressed on tumor cell surfaces may inter-
fere with adhesion molecules that some tumor cells need to survive. 
• IgG antibodies, can mediate tumor cell lysis through antibody dependent cell–
mediated cytotoxicity (ADCC), involving effector cells such as macrophages, nat-
ural killer (NK) cells, CD8+ T cells and perhaps blood neutrophils. 
Oncogenic proteins are encoded by oncogenes or by tumour suppressor genes, or 
both, and play a part in the control of cell growth and differentiation. Antibody immun-
ity to a number of oncogenic proteins has been identified over the last several years. 
However, production of these antibodies does not confer protection, but, paradoxically, 
correlates with poor prognosis and decreased survival for several human cancer types 
[101]. Increased levels of immunoglobulins (Ig) in neoplastic microenvironments also 
result in accumulation of immune complexes (ICs) that engender tumor-promoting in-
flammatory responses [102]. Ig-IC formation is a significant feature of cancer devel-
opment. High circulating levels of ICs are associated with increased tumor burden and 
poor prognosis in patients with breast, genitourinary, and head and neck malignancies, 
Ig deposition in neoplastic stroma has been reported in pre-malignant and malignant 
human breast and prostate tissues [103, 104, 105]. While investigators are using the 
presence of antibody immunity as an indicator for a potential T-cell response, and, 
thus, identification of T-cell antigens that may be exploited for therapy, antibody im-
munity on itself may have great utility in the diagnosis and management of human 
malignancy. 
Antibody immunity to a number of oncogenic proteins has been identified over 
the last several years. The representative ones are those against P53, HER-2/neu, ras, 
c-myc, bcr-abl and recently, Survivin. 
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Antibody response to P53 
The antibody immune response to p53 has received the most attention. This is 
basically because mutations in the p53 gene are common, and occurring in approxi-
mately 50% of all human cancers. P53 is a tumor suppressor gene, and mutations that 
occur in the gene cause inactivation of encoded p53 protein. Antibody immunity to the 
p53 protein has been reported for nearly every human tumor with which p53 muta-
tions are associated: colon, breast, ovarian, lung and gastric cancer to name a few 
[106]. The incidence of these antibodies in the serum of patients with cancer ranges 
from 10% to 50% of patients evaluated in an each individual study. A p53 specific an-
tibody response may eventually be developed as a diagnostic or prognostic tool in 
monitoring the therapy of many types of cancers.  
It has been shown that patients with various types of neoplasias have p53 anti-
bodies in their sera. ELISA was used to detect anti-p53 antibodies in the sera of 167 
patients with lung cancer. Among these, 32 individuals (16 positive for p53 antibodies 
and 16 negative) were monitored over a period of 30 months for p53 antibodies. 
Twelve of 16 antibody positive patients had reduced titers during chemotherapy more 
than 50% compared to the initial titer. Among these patients, eight underwent a com-
plete response to therapy, whereas four obtained only a partial response, that led to 
partial or complete remissions of disease and 4 had no change in the level of p53-Ab, 
or else had a decrease of less than 50%. The specificity of these antibodies was con-
firmed by two different ELISA procedures and by immunoprecipitation. The very rapid, 
specific decrease in these antibodies during therapy suggests that a constant level of 
tumoral cells with nuclear accumulating p53 protein is necessary for a detectable hu-
moral anti-p53 response. The good correlation found between the specific evolution of 
the p53 antibody titer and the response to therapy suggests that p53 antibodies could 
represent a useful tool for checking the response to therapy and for monitoring some 
relapses before they are clinically detectable [107]. 
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Antibody response to HER-2/neu 
The HER-2/neu protein is a member of the epidermal growth factor receptor 
family and it’s a self-protein that is expressed by some normal tissues but is often 
overexpressed by a variety of cancer cells. The presence of endogenous HER-2/neu-
specific antibodies has been identified in breast (11%), prostate (15.5%) and colorec-
tal cancer patients [108 , 109]. 
Antibody response to ras protein 
Three ras genes, H-ras, K-ras and N-ras, have been defined, and these genes en-
code a 21 kDa protein designated as p21 ras. Antibodies to p21 ras proteins have been 
detected in patients with colon cancer, by using ELISA and purified ras proteins. Sera 
were examined from 160 colon cancer patients and 60 normal controls to determine 
whether antibodies to mutated p21 ras protein were present. Antibodies of IgA sub-
type against mutated p21 ras protein were detected in 51 of 160 (32%) colon cancer 
[110]. 
Antibody response to c-myc protein 
The c-myc protein belongs to the myc oncoprotein family which also includes N-
myc and L-myc. Circulating antibodies to the myc protein have been detected in can-
cer patients. Serum antibodies to myc were first described in 4 of 6 (67%) of patients 
with colon cancer, 12 of 125 (10%) of breast cancer patients, 1 of 2 (50%) osteosar-
coma patients, 1 of 9 (11%) ovarian cancer patients, and 3 of 3 (100%) of patients 
with cancer of unknown origin [111]. In a study the serum c-myc antigens and anti-
bodies against c-myc were examined in 68 lung cancer patients and 30 healthy volun-
teers. Anti-c-myc antibodies were detected in 9 of 68 (13.2%) patients with lung can-
cer and 1 of 30 (3.3%) of normal controls [112]. 
Antibody response to bcr-abl 
The molecular hallmark of chronic myelogenous leukemia (CML) is the Philadel-
phia (Ph) chromosome, which results from a reciprocal translocation of human c-abl 
proto-oncogene from chromosome 9 to the bcr region on chromosome 22. A study was 
performed to demonstrate the presence of antibodies against p210 Bcr-Ab in both, Ph-
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positive and Ph-negative leukemia patients, and in healthy volunteers. Plasma from 18 
of 31 (58%) individuals was able to immunoprecipitate p210 Bcr-Abl including 14 of 20 
patients (70%) with Ph-positive CML. Plasma of 2 of 7 (29%) normal subjects also 
contained p210 specific antibodies [113]. 
1.4.3. Antibody response to survivin 
Previous reports show that survivin is expressed at high levels in a number of 
human tumours [80]. Concurrently, it has been demonstrated that survivin epitopes 
are present on a broad variety of malignancies prompting the development of both, 
cellular and humoral immune responses [93]. It has been suggested that survivin is 
associated with tumor progression and poor prognosis of patients with brain tumors. 
Survivin-specific antibodies were detected by using ELISA in patients with brain tu-
mours , and it  were detected in 5 of 42 (11.9%) patients with meningiomas and 3 of 
35 (8.6%) patients with malignant gliomas, but not in healthy controls. Tumors of pa-
tients with detectable anti-survivin antibodies demonstrated survivin expression in at 
least 20% of the tumor cells as assessed by immunohistochemistry. This study con-
cludes that patients with meningiomas and malignant gliomas can mount a high titer 
IgG immune response against the ‘universal’ tumor associated antigen survivin [114]. 
Anti-survivin antibody responses in patients with head and neck cancer were 
investigated by ELISA. High levels of anti-survivin were detected in patients with ad-
vanced stage. Interestingly, levels of anti-survivin fell after curative treatment. Moreo-
ver, 92.3% tested patients were positive for at least 1 of 3 markers. These findings 
demonstrated that anti-survivin antibody is present in the sera of a majority of pa-
tients with head and neck cancer [115]. 
Detection of autoantibodies to survivin in sera from patients with chronic hepa-
titis (CH) (57 patients) and hepatocellular carcinoma (HCC) (29 patients) by using 
ELISA, showed anti-survivin antibodies in 10 of 57 sera (17.5%) of (CH); and in 7 of 
29 sera (24.1%) in HCC. These prevalence rates were consistent with results of previ-
ous studies [116, 117]. In addition, the levels of anti-survivin antibodies in HCC pa-
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tients with hepatitis C virus (HCV) infection were significantly higher than those in the 
healthy controls and HCC patients with hepatitis B virus (HBV) infection. However, 
there were no significant differences in the levels of anti-survivin antibodies between 
HCV patients and HCC patients with HCV infection. Also, there were no significant dif-
ferences in the levels of anti-survivin antibodies among the healthy controls, HBV pa-
tients and HCC patients with HBV infection. These results suggest that the levels of 
anti-survivin antibodies have no association with the progression of HCV or HBV to 
HCC [118]. 
The prevalence of anti-survivin and livin antibodies was examined in breast 
cancer patients with a specific enzyme linked immunosorbent assay (ELISA) using full 
length recombinant protein.  Anti-livin antibodies were detected in excess of cutoff 
values in 15 of 46 breast cancer patients (32.6%), while anti-survivin were detected in 
11 of 47 (23.9%). Sera from 46 breast cancer patients were assessed simultaneously 
with the anti-survivin and anti-livin ELISAs. Twenty-four sera (52.2%) were positive 
for 1 or both ELISAs using the respective proteins. These results suggest that combi-
nation ELISA for anti-livin antibodies and anti-survivin antibodies may be useful in de-
tection of breast cancers [119]. 
To investigate the prevalence of mucosal autoantibodies to survivin in patients 
with human papillomavirus (HPV) associated cervical cancer and precursor lesions, 
cervical mucus from 117 HPV-associated cervical cancer and 80 normal controls were 
tested by ELISA using either full length recombinant survivin or survivin-derived pep-
tides. This study reported that an increasing proportion of patients with cervical cancer 
(28.2%) have mucosal IgA antibodies reactive against recombinant survivin. Addition-
ally, it showed that antibodies to survivin are detected in patients with oncogenic HPV-
associated pre-malignant lesions and that the presence of such antibodies is related to 
the grade of lesion and to the level of expression of survivin in the cervical tissue 
[120]. 
To detect anti-survivin antibody in gastrointestinal cancer patients, blood sam-
ples were collected from 33 healthy blood donors and 63 gastrointestinal cancer pa-
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tients. 25 of 63 gastrointestinal cancer patients (39.7%) were reactive with recombi-
nant survivin protein by ELISA, whereas none of the control sera from healthy donors 
was reactive. In this study, antibody responses against survivin were not always ap-
parent in all patients whose cancers expressed survivin; these results suggest that the 
site of tumor origin influences anti-survivin reactivity [116]. 
Another approach was performed to determine whether a mini-array of multiple 
TAAs would enhance antibody detection and be a useful approach to cancer detection 
and diagnosis. The mini-array of TAAs comprised full-length recombinant proteins ex-
pressed from cDNAs encoding c-myc, p53, cyclin B1, p62, Koc, IMP1, and survivin. En-
zyme immunoassay was used to detect antibodies in 527 sera from six different types 
of cancer. Antibody frequency to any individual TAA was variable but rarely exceeded 
15–20%. With the successive addition of TAAs to a final total of seven antigens, there 
was a stepwise increase of positive antibody reactions up to a range of 44–68%. 
Breast, lung, and prostate cancer patients showed separate and distinct profiles of re-
activity, suggesting that uniquely constituted antigen mini-arrays might be developed 
to distinguish between some types of cancer. This study concluded that the detection 
of autoantibodies in cancer can be enhanced by using a mini-array of several TAAs as 
target antigens [117]. 
Detection of anti-survivin antibodies in the sera of lung (n=51) and colorectal 
(n=49) cancer patients was performed using ELISA.  Eleven sera from lung cancer pa-
tients (21.6%) and four sera from colorectal cancer patients (8.2%) reacted with puri-
fied recombinant survivin. This is in agreement with [121], where a higher prevalence 
was seen for anti-survivin antibodies in patients with lung cancer. 
Another study was conducted to detect autoantibodies to livin and survivin in se-
ra from lung cancer patients. A cutoff value for positivity was determined as the mean 
absorbance +2SD for healthy control samples. As a result, 19 of 37 lung cancer pa-
tients (51.3%) were positive for anti-livin antibodies and 18 of 31 (58.1%) were posi-
tive for anti-survivin antibodies. Sera from 31 lung cancer patients were further as-
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sessed simultaneously using anti-survivin and anti-livin ELISAs and 21 of them (71%) 
were positive for survivin, livin, or both. This suggests that antibodies against both 
survivin and livin were detected in lung cancer patients, which implies that sensitive 
assay for these antibodies can be used in combination for the detection of lung cancer. 
Nevertheless, further studies are necessary for the confirmation of this suggestion 
[122]. 
1.4.4. Antibody response affected by chemotherapy 
Over the past decade, a number of new agents have become available for the 
treatment of metastatic non–small-cell lung cancer, including the taxanes, gemcita-
bine, and Vinorelbine. Most cytotoxic drugs have gross effects on the immune system, 
such as neutropenia and lymphopenia. However, their effects on tumor-specific im-
mune responses are unknown. 
Gemcitabine is a nucleoside analogue that is frequently used to treat non-small 
cell lung cancer. In a study conducted to investigate the effects of gemcitabine on an-
tigen-specific antitumor immunity using a murine tumor cell line transfected to express 
influenza virus hemagglutinin (HA) , it was found that gemcitabine massively depletes 
lymphocyte numbers. Nevertheless it has a selective detrimental effect on the B-
lymphocyte subset associated with a complete ablation of the antitumor antibody re-
sponse [123]. 
Previous studies regarding chemotherapeutic agent immunotoxicity have not re-
ported any selective B-lymphocyte toxicity. Most studies on patient populations have 
been performed in groups receiving combination chemotherapy, and thus it is difficult 
to separate the effects of any one agent. Children and young adults undergoing inten-
sive chemotherapy for solid tumors and lymphomas have been studied for changes in 
peripheral blood lymphocyte populations following maximal hematological recovery 
after several chemotherapy cycles. It was reported that lymphocyte recovery did not 
occur between cycles in these patients, leading to severe B- and T-cell depletion 
[124]. B cells were nearly undetectable, and IgM was absent in 50% of the patients 
studied, whilst IgG levels were normal. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 05:48:26 EET - 137.108.70.7
Anti-survivin autoantibodies in lung cancer 
Page 40 of 83 
1.5. Aim of the project 
As a consequence to the selective expression of survivin by malignant tissue, 
and the fact that it is ubiquitously expressed and required for maintenance of cancer 
cell growth, survivin has been considered as an attractive target in cancer immuno-
therapy protocols [125 , 126]. To this end, elegantly performed studies have identified 
spontaneous immune responses elicited by peptides of survivin [90, 92, 93,  127]. 
Humoral anti-survivin responses, on the other hand, mainly investigated in the context 
of cancer diagnosis and/or follow up, have been detected in patients with various 
forms of cancer, with a prevalence of antibody varying between 10% and 60% de-
pending on the method utilised, the source of antigen and the type of cancer [116, 
119, 121, 128]. In the same context, anti-survivin antibodies have been examined in 
patients with lung cancer. To the best of our knowledge, there are only 3 studies in 
small cohorts of patients, uncovering frequencies of anti-survivin antibodies in lung 
cancer varying between 10.7% and 58%, and also presenting inconsistent results re-
garding the levels of antibodies and their correlations with the type of cancer or the 
clinical parameters of the disease [117, 121, 122 ]. 
Our recent findings demonstrating a very low immunogenicity of survivin re-
garding the induction of CTL responses [129], coupled by the inconclusive results con-
cerning the humoral anti-survivin response as described above, impose the need for a 
comprehensive and thorough investigation of anti-survivin antibodies in lung cancer. 
This study was scheduled in order to investigate in a large sample of patients with lung 
cancer and normal controls, the frequency and the levels of circulating anti-survivin 
antibodies. Their correlations with the parameters of the tumor and the disease were 
also explored. Finally, under the light of the reported immunomodulatory effects of ra-
diotherapy and various chemotherapeutic agents used in lung cancer, like platinum, 
taxanes, gemcitabine, etc, their possible effect on the levels of anti-survivin antibodies 
was examined [130, 131]. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 05:48:26 EET - 137.108.70.7
Anti-survivin autoantibodies in lung cancer 
Page 41 of 83 
2. MATERIALS AND METHODS  
2.1. Serum samples 
One hundred and fifty patients with lung cancer were examined. Thirty three of 
these were diagnosed with small cell lung cancer (SCLC) (31 males and 2 females, 
mean age 62.1±9.9years) and 117 with non-small cell lung cancer (NSCLC) (108 
males and 9 females, mean age 64.2±9.3 years). In 22 patients with SCLC and 76 
with NSCLC serial samples were collected post therapies (various combinations of sur-
gery and chemotherapy including adjuvant chemotherapy) and during follow-up (those 
of interest are presented in results). The characteristics of the patients and their tu-
mors are shown in (Table 2). Serum samples from 100 apparently healthy individuals 
served as controls (99 males and one female, mean age 68.2±5.8 years). The study 
conforms to the provisions of the Declaration of Helsinki, it was reviewed and ap-
proved by the University of Thessaly Ethics Committee, and all participants provided 
informed consent. Serum samples from patients and normal subjects were collected, 
aliquoted and stored at -80°C until the moment of testing. 
2.2. Antigen 
Survivin was purchased as full length recombinant protein with GST tag, (BIRC5) 
(1aa-142aa) from Abnova, USA (Cat. No H00000332-P01,) and was kept at -800C. 
2.3. Buffers  
Plates were coated with Carbonate/Bicarbonate buffer (pH 9.6) (Cat. No C3041, 
Sigma, USA). For each experiment, one capsule of 0.05M carbonate/bicarbonate buffer 
was dissolved in 100mL distilled water and stirred until completely dissolved. The pH 
was adjusted to 9.6 using 5M HCL and stored in a sterile container. 
To wash the plates two buffers were used: a). Phosphate Buffered Saline pH 7.4 
(PBS) (Cat. No P5368, Sigma) and, b). PBS with 0.01% Tween 20 (Cat. No P9416, 
Sigma). 
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To block the non-specific binding sites on the plate, 5% Bovine Serum albumin 
BSA/ PBS (Cat. No A7888, Sigma) was freshly prepared for each experiment. 
Table 2:  Characteristics of patients and normal controls included in the study. 










































           











































& ECOG Performance status; # 0= Less than 5% weight loss; 1 = Loss of weight >5%; 
**Alive = 0, Dead = 1 
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2.4. Reagents  
Several reagents were used in this study as explained below: 
Goat polyclonal to survivin with a concentration 0.50mg/mL was used for ELISA 
optimization (Cat. No 27468 Abcam, USA). 
Rabbit polyclonal to goat IgG H&L (HRP) (Cat. No 6741, Abcam,) with a concen-
tration 2mg/mL, was used as secondary antibody. 
Anti-human HRP-conjugated secondary antibody, TMB chromogen developing 
agent, in addition to HRP stop solution were purchased from (Inova-San Diego, USA) 
and were used as recommended by the company. 
2.5. Equipment 
Plate Reader which supplied by (DAS Company, Italy) is an eight channel pho-
tometer for the sequential and simultaneous reading of micro-plate strips with 96 
wells, with two optical filters (450 & 630 nm) and shaking capability. 
Flat bottom 96 well cell cultures with lid, nonpyrogenic, polystyrene and sterile 
plates, supplied by (Costa USA) were used. 
2.6. ELISA (Enzyme-Linked ImmunoSorbant Assay) 
An ELISA was used to detect anti-survivin antibody in the blood of patients with 
lung cancer. ELISAs are performed in 96- well plates which permitting high throughput 
results. The bottom of each well is coated with a protein to which the antibody we 
want to be measured will bind. 
2.6.1 Overview of methodology 
The (ELISA) is the most commonly used antibody or antigen detection method. 
Preparation of ELISA microtiter plates involves three major steps: 1) binding antigen 
or antibody to the plate; 2) blocking non-specific binding sites on the plate; and 3) de-
veloping the plate to read each sample’s OD. 
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The first step in making a reliable ELISA is proper coating of the antigen onto the 
plate, also coating buffers should stabilize coated proteins, and this allow greater bind-
ing reactivity with the detection molecule, thereby enhancing the specific signal. De-
termination of optimal antigen concentration (or dilution) is one of the mandatory 
steps in developing an ELISA. 
Plates were coated with survivin recombinant protein (BIRC5) in 0.05 M car-
bonate buffer, pH 9.6 overnight at 40C, and then plates were washed 4 times with 
0.1% T20/PBS and 4 times with PBS, non-specific binding was prevented by adding 
blocking buffer and incubation overnight at 4°C. Primary antibody was added in dupli-
cate in the microtiter plate wells, a positive control and a negative control are also in-
cluded. Sera from different patients can be used concurrently (Fig. 8). 
Figure 8: In indirect ELISA, the production of color indicates the amount of an anti-
body to a specific antigen. 
After sufficient incubation at room temperature, the primary antibody is removed 
and weakly adherent antibodies are washed off as mentioned before. To detect the 
bound antibodies, a secondary antibody is added to each well and incubated for I hour 
at room temperature. The secondary antibody would bind to all human or goat anti-
bodies. Attached to the secondary antibody is an enzyme. The enzyme can metabolize 
colorless substrates into colored products. After an incubation period the secondary 
antibody solution is removed and washed as before. Chromogen reagent was added 
for 1 hour at room temperature and plates were washed as before. When the enzyme 
reaction is complete, the entire plate is placed into a plate reader and the optical den-
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sity (i.e. the amount of colored product) is determined for each well. The amount of 
color produced is proportional to the amount of primary antibody bound to the proteins 
on the bottom of the wells. 
2.6.2. Optimization of blocking buffers 
It is important to block the unoccupied sites on the surface of the well to reduce 
the amount of nonspecific binding of proteins during subsequent steps in the ELISA 
assay. The blocking buffer improves the sensitivity of the assay by reducing the back-
ground interference. A variety of blocking buffers in PBS, like skimmed milk (SM), hu-
man serum albumin (HAS) and (BSA) were tested to block un-reacted sites. To opti-
mize blocking temperatures microtiter plates wells were blocked and incubated over-
night at 4°C and 37°C with 5%: ΒSA/PBS, HAS/PBS, SM/ PBS. Blocking overnight with 
5% BSA/PBS at 4°C was found to diminish significantly non-specific binding (Fig.9A 
and 9B). 
2.6.3. Optimization of antigen concentration 
The optimal concentration of survivin recombinant protein was determined as a 
coating antigen. 96-well microtiter plates were coated with 100 µL survivin full length 
recombinant protein concentrations between 10µg/mL and 0.3125 µg/mL in 0.05M 
carbonate buffer, pH 9.6, and plates were incubated overnight at 4°C. After removing 
the antigen solution, plates were washed. Non-specific binding was prevented by 
blocking overnight at 4°C with 5% ΒSA/PBS. After emptying the wells, plates were 
washed and, goat polyclonal anti-survivin antibody added at concentration 1 µg/mL as 
recommended by the company and the plates were incubated one hour at room tem-
perature. Plates were washed again and rabbit polyclonal to goat IgG at dilution 
1:16000 was added for 1 hour at room temperature and anti-survivin antibodies de-
tected using chromogen reagent. 50% absorbance was calculated to be at 2 µg/mL 
survivin. (Fig.10). Similar titrated analyses were then performed for patients’ sera at 
dilution 1:40 (Fig. 11). 
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Figure 9: (A) Incubation overnight at 4°C or (B) Incubation overnight at 37°C. 
Blocking with 5% SM/PBS (black), with 5%HAS/ PBS (grey) and 5%BSA/PBS (white). 
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Figure 10: Antigen concentration optimization. Microtiter plates were coated and incubat-




Figure 11: Antigen concentration optimization. Microtiter plates were coated and incubated with 
patient serum at dilution 1: 40. Absorbance was measured at 450 nm using an ELISA plate 
reader. 
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2.6.4. ELISA to measure anti-Survivin antibodies 
Having setup the conditions of the ELISA, anti-survivin antibodies were meas-
ured. Plates were coated with 100 µL of a 2 µg/mL recombinant survivin protein 
(BIRC5) in 0.05 M carbonate buffer, pH 9.6 for 20 hours at 4°C. After removing the 
antigen solution, plates were washed 4 times with 0.1%T20/PBS and 4 times with 
PBS; non-specific binding was prevented by blocking for 20 hours at 4°C with 5% 
ΒSA/PBS. After emptying the wells, plates were washed as before and serum was add-
ed as duplicates for 1 hour at ambient temperature. A dilution of 1:40 in 1% BSA/PBS 
was used as it was proved appropriate for the discrimination between background 
noise and positivity [132]. Plates were washed as before and sheep anti-human IgG 
labeled with horse radish peroxidase (HRP) was added for 1 hour at ambient tempera-
ture and anti-survivin antibodies detected using chromogen reagent. Absorbance was 
measured at 450 nm using an ELISA plate reader. 
Since sera could not all be tested at the same time and to eliminate inter-assay 
variability, each run of experiments included 1 positive serum sample (PS). All test se-
ra were normalised against the ODs obtained each time against this serum and rela-
tive absorbance units were calculated as follows: Relative Absorbance Units (RAU) = 
(OD test sera  — blank)/(ODPS — blank) x 100. Sera with an RAU>mean+2SD of the 100 
normal sera were considered positive only after they were re-tested at serial dilutions. 
To examine the performance of the ELISA, 3 different sera (1 with high, 1 with 
moderate and 1 with low anti-survivin antibody levels) were used. The inter-assay var-
iability never exceeded 10% whereas intra-assay variability consistently ranged be-
tween 0% and 15% 
2.6.5. Sera titration experiments 
All positive sera from lung cancer patients were further diluted: 1/13, 1/40, 
1/120/, 1/360, 1/1080 and 1/3241 in 1% BSA/PBS, and then subjected to ELISA as 
described before. 
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2.6.6. Preabsorption of sera with survivin. 
To determine the specificity of the ELISA, all positive sera were pre-absorbed 
with the recombinant survivin. Serum samples (100 µL of a 1:100 dilution) were incu-
bated with 30 µg/mL of recombinant survivin for 6 hours at 37 °C and then subjected 
to the anti-survivin ELISA as described above. After absorption, reactivity decreased 
significantly returning to values similar with those obtained by normal sera (Fig.13) 



















Figure 13: Specificity of survivin recognition was confirmed by lack of reactivity after Pre-
absorption of sera with survivin protein. 
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2.7. Statistical analysis 
Expression values are presented as mean±SD. Students’ t-test, ANOVA, Fisher’s 
exact test spearman’s bivariate correlation and linear regression analysis were appro-
priately used. All analysis were performed with statistical software SPSS for Windows 
(version 11.5). 
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3. RESULTS 
Upon diagnosis, patients with NSCLC had significantly higher levels of anti-
survivin antibodies (11.5±15.2 RAU) both against patients with SCLC (3.1±2.1 RAU) 
and normal individuals (7.7±7.3 RAU) (Mann-Whitney U test, p<0.001, p=0.009, re-
spectively) (Fig. 14). When a cutoff value for positivity was set to 20.9 RAU 
(mean+2SD of the normals), 9/117 (7.7%) patients with NSCLC appeared with an in-
creased anti-survivin antibody level prior to therapy (46.3±33.5 RAU) versus none of 
the SCLC and 2% of the normal individuals. Differences in positivity observed amongst 
patients, did not differ significantly from that of controls neither in the case of NSCLC 
(odds ratio 3.6, 95% confidence interval 0.7-17.3) nor in that of SCLC patients (odds 
ratio 0.6, 95% confidence interval 0.03-12.6). 
We next examined whether the levels of anti-survivin antibodies upon diagnosis 
correlated with any clinicopathological parameter (age, sex, performance status, loss 
of weight, stage of disease) and response to treatment (surgery, chemotherapy, and 
radiotherapy). No significant correlations were uncovered with either patient group 
(Table 3). Moreover, the overall survival time did not differ between patients with an-
tibody levels greater or lesser than the cutoff value for positivity (20.9 RAU) (Fig 15A). 
The patients with an antibody value upon diagnosis >20.9 RAU had an overall median 
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Figure 14: Anti-survivin antibodies detected by ELISA in sera from patients with 
NSCLC (n=117) and SCLC (n=33) in comparison to sera from age and gender 
matched healthy individuals (n=100). The results are mean values of two determina-
tions and are represented as Relative Absorbance Units (RAU). The horizontal line indi-
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Table 3: Correlations of anti-survivin antibody levels upon diagnosis with clinicopathological pa-
rameters and treatment for all patients (n=150). 
*p values were obtained after comparing for each group the antibody levels and every pa-
rameter; & ECOG Performance status; # Treatment refers to surgery and/or radiotherapy 
and/or chemotherapy and PD: progressive disease; PR: partial response; DF: disease free; 



















 Anti-survivin antibodies 
  n Median (range) p-value 
Age ≤65 82 5 (1-114) 0.087 
 >65 68 7.5 (1-77)  
Sex M 139 6 (1-114) 0.681 
 F 11 6.8 (3-28)  
Performance Status& 0 91 6 (1-114) 0.949 
 1 43 8 (1-82)  
 2 10 8 (1-15)  
 3 6 5.5 (3-20)  
Loss of weight <5% 105 6 (1-114) 0.753 
 ≥5% 45 6 (1-82)  
Stage I–II 30 8 (1-19) 0.270 
 III-IV 120 6 (1-114)  
Response to Treatment# PD 28 7 (1-82) 0.256 
 DF 19 7 (4-34)  
 CR/PR 30 4 (1-114)  
 SD 21 5 (1-28)  
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Figure 15: Kaplan-Meier survival curves. A: The overall survival time for all patients 
(n=150) is calculated on the basis of antibody levels upon diagnosis greater or lesser 
than the cutoff value for positivity (20.9 RAU) (median survival time: <20.9 =415 days, 
>20.9 =452 days, p=0.395). B: The overall survival time for patients with an increase 
or decrease in antibody levels post treatment is indicated (median survival time: in-
crease in antibodies =781 days, decrease in antibodies =452 days, p=0.110). 
Considering that for an antibody response to occur, an antigen needs to be seen 
by the immune system, resected tissues from 24 patients (NSCLC) were examined for 
the presence of mRNA transcript expression in a previous study of ours [46]. All the 
examined patient samples, representing a proportion of those tested for antibodies, 
expressed variable levels of survivin mRNA transcripts (Table 4). The expression levels 
appeared to be unrelated to the detected anti-survivin antibodies pre or post thera-
pies, since even with a negligible antigen expression, antibodies could be detected. 
Interestingly however, as we had noted before [129], when we examined whether 
survivin specific CD8+ T cell precursors could be identified in the peripheral blood of 
some of these patients, none could be detected (Table 4). These findings suggest that 
the expression of survivin, does not necessarily relate to the anti-survivin B and T cell 
responses. 
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Table 4: Humoral and cellular responses of the NSCLC patients and the survivin mRNA expres-
sion levels in their respective tumor samples. 
Patient No Antibody levels* T cells** 
Survivin expression 
levels& 
 pre post   
9 12 NT&& NT 23.5 
15 16.3 22.5 <2.7 <1 
22 4.5 NT NT <1 
24 34 14 NT <1 
27 4.6 5.8 NT <1 
29 6.3 NT <2.6 11.2 
30 5.6 4.1 <1 75.3 
32 6.8 4.1 <4.3 <1 
39 18.2 16.3 <1 45.2 
43 9 9.3 <3 5.1 
50 12.6 NT <4.3 8.7 
52 113.9 84.9 <3.6 21.3 
56 6.8 11.8 <2.4 12.5 
57 3.6 54.2 <1.5 <1 
59 10.6 64.7 NT 21.7 
68 5.7 5.8 NT <1 
70 11.1 13.1 <3.8 18.2 
76 4.7 5.6 <7.2 6.2 
77 9.9 8.6 NT <1 
84 0.7 26.9 <5 25.5 
89 3 4.0 NT 8.5 
93 3.6 3.3 NT <1 
100 3.9 22.3 NT <1 
101 8.9 10.1 <6.3 37.6 
*Antibody levels pre and post therapies and values represent RAU; **Peptide specific CD8 
T cell responses measured at the time of diagnosis as described previously [129]. Values 
represent frequency per 10 million peripheral blood CD8 T cells; &Survivin mRNA expres-
sion levels in tumor samples adjusted to the expression in a testis reference sample (<1 
expression level is considered as negative)  as described previously [46]; && NT: Not test-
ed. 
 
Changes to the levels of anti-survivin antibodies in the NSCLC patients examined 
post therapies and during follow-up (n=76) were not statistically significant (repeated 
measures one-way analysis of variance with Bonferroni correction, p>0.05). However, 
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in 12 of these patients, with NSCLC, a significant increase by 2-38 (mean 8.2 ±10.4) 
times in the antibody levels was observed (p=0.02) that remained post therapies dur-
ing follow-up. In 7 other NSCLC patients (one of them having not received any kind of 
therapy), a decrease was observed by 2-8 times (mean 0.4 ±0.14). Figure 16 presents 
representative patients with an increase or decrease in antibody levels post treatments 
and during follow-up whereas Table 5 presents the characteristics of all NSCLC pa-
tients examined post therapies and during follow-up. 
We next examined whether in the NSCLC patients (n=19) alterations in the anti-
body levels correlated with the clinicopathological parameters (age, sex, performance 
status, loss of weight, stage of disease) and response to treatment (Table 6). No sig-
nificant correlations were identified against any parameter examined, with the excep-
tion of a weak non-significant relation with an early stage of disease (p=0.054). Fur-
thermore, the overall survival time between patients with an antibody increase or de-
crease post therapies and during follow-up did not present with any significant differ-
ence (Fig 15B). The patients with an increase in the antibody values post treatment 
had an overall median survival time of 781 days vs 452 days for patients with a de-
crease (p=0.110). 
The strength of the antibody response was further evaluated. All positive sera 
were serially titrated. As presented in Fig 17, positive sera contained significant levels 
of anti-survivin antibodies with an average titre of 1/1270 which was clearly different 
from the two positive sera from normals that had an average titre of 1/360. 
Finally, to ascertain whether treatment-induced lymphopenia was associated with 
alterations in anti-survivin antibody levels of NSCLC patients (n=76), correlations were 
determined between type of treatment and chemotherapy protocols (Table 7). No sta-
tistical significance was uncovered between any of the examined parameters and the 
antibody changes (p>0.05). 
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Table 5 Characteristics of NSCLC patients with or without variations in anti-survivin antibody 
levels. 
 Antibody variations* 
  (n=7)  (n=12) NC 
(n=57) 
Antibody change mean±1SD 0.4±0.14 8.2±10.4 1±0.3 
Age (mean±1SD) 68.3±5.9 62.2±9.2
 64.3±9.4 
Sex (male/female)  6/1 11/1 50/7 
Stage  
I 1 1 9 
II 0 3 5 
III 4 3 21 
IV 2 5 22 
Performance& 
0 3 8 40 
1 3 3 16 
2 0 1 1 
3 1 0 0 
Loss of weight 
<5% 2 10 45 
>5% 5 2 12 
Treatment 11 18 53 
Surgery 2 4 16 
Chemotherapy 4 8 39 
Radiotherapy 1 3 11 
Disease Status after treatment# 
PD 3 4 15 
CR/PR 2 1 13 
DF 1 4 14 
SD 1 3 15 
* = Number of patients with antibody levels >2x pre-treatment value,  = Number of patients 
with antibody levels <0.5x pre-treatment value, NC = Number of patients with no change in an-
tibody levels; & ECOG Performance status; #PD: progressive disease; PR: partial response; DF: 
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Figure16: Anti –survivin antibody variation in patients pre and post therapies. Plots represent 
Relative Absorbance Unit(y axis) observed during follow –up (x axis; days). 
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Figure 17: Positive sera titration. Y axis presents the OD at 450nM and x axis presents 
serum dilutions.  
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Table 6: Correlations of anti-survivin antibody level variations post treatment with clinicopatho-
logical parameters and treatment in patients with NSCLC (n=19)*. 
*p values obtained after comparing antibody level variations (before and after treatments) 
with every parameter; & ECOG Performance status; # Treatment refers to surgery and/or 
radiotherapy and/or chemotherapy and PD: progressive disease; PR: partial response; DF: 







 Anti-survivin antibodies 
  n Median (range) p-value 
Age ≤65 12 13 (2-72) 0.165 
 >65 7 8 (4-27)  
Sex M 17 11 (4-72) 0.781 
 F 2 28 (2-54)  
Performance Status& 0 11 18 (2-72) 0.876 
 1 6 6 (4-27)  
 2 1 11  
 3 1 8  
Loss of weight <5% 12 15 (2-72) 0.091 
 ≥5% 7 8 (4-27)  
Stage I–II 5 54 (7-72) 0.054 
 III-IV 14 10 (2-27)  
Response to Treatment# PD 7 8 (2-13) 0.095 
 DF 3 7 (4-18)  
 CR/PR 5 54 (14-72)  
 SD 4 14 (5-27)  
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Table 7:  NSCLC patients with alterations in anti-survivin antibody levels in relation to 
chemotherapy treatment.  
 
* = Number of patients with antibody levels >2x pre-treatment value,  = Number of pa-
tients with antibody levels <0.5x pre-treatment value, NC = Number of patients with no 
change in antibody levels; #Number of patients who received adjuvant platinum-based 
chemotherapy; **Number of patients submitted to surgery; ##Number of patients who re-





change* Adj# S** R## L& 
  NC 
Paclitaxel (175 mg/m2) + Vinorelbine (25 mg/m2) 0 0 1 0 0 0 0 
Paclitaxel (175 mg/m2) + Gemcitabine (103 mg/m2) 0 0 2 0 0 1 1 
Paclitaxel (175 mg/m2) + Carboplatin (6 AUC) 3 3 16 4 5 7 7 
Docetaxel (75 mg/m2) + Carboplatin (6 AUC) 1 1 5 0 0 2 2 
Carboplatin (6 AUC) + Vinorelbine (25 mg/m2) 0 0 1 0 0 0 1 
Carboplatin (6 AUC) + Gemcitabine (103 mg/m2) 1 0 7 0 0 3 2 
Cisplatin (75 mg/m2) + Gemcitabine (103 mg/m2) 3 0 4 2 2 1 3 
Cisplatin (75 mg/m2) + Vinorelbine (25 mg/m2) 4 2 9 9 10 7 5 
Cisplatin (75 mg/m2) + Docetaxel (75 mg/m2) 0 0 3 0 0 1 1 
No chemotherapy 0 1 9 0 5 1 2 
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4. DISCUSSION  
Since the mid-1970’s, there has been an increasing demand for sensitive, rela-
tively simple assays for use in basic research and clinical diagnosis. Over the same pe-
riod, many practical considerations have led to the need to adapt existing assays and 
to develop novel ones without the use of radioisotope tracers, which have been com-
monly used in assay development for decades. The assay format that most closely 
meets all of these criteria in many situations is the Enzyme-Linked Immunosorbent 
Assay (ELISA). Today, most ELISAs follow one of three strategies: Indirect ELISA, typ-
ically used to screen for antibodies; Sandwich (or antigen capture) ELISA, to assay the 
amount of target antigen which is present; or Competitive ELISA, to define antigenic 
specificity or to increase the specificity of an assay when samples contain cross-
reacting species. Choosing the best format depends on the intended application of the 
assay; the type of samples to be analyzed; the availability of reagents. 
There are many parameters which influence the results obtained in an ELISA. 
These include: antibody quality and concentrations, incubation times, incubation tem-
peratures, blocking & detection reagents and its concentration, and substrate type and 
quality. The ELISA screening system established in this study has been standardized 
using goat mAbs with specificity for survivin recombinant antigen. 
The blocking buffer should improve the sensitivity of the assay by reducing the 
background interference. An individual blocking buffer will not be compatible with eve-
ry system; for this reason, a variety of blockers in both Tris buffered saline (TBS) and 
phosphate buffered saline (PBS) are available. The most important parameter when 
selecting a blocker is the signal/noise ratio, measured as the signal obtained with a 
sample containing the target analyte, as compared to that obtained with a sample 
without the target analyte. Using inadequate amounts of blocker will result in exces-
sive background and a reduced signal: noise ratio. Using excessive concentrations of 
blocker may mask antibody-antigen interactions or inhibit the enzyme, again causing a 
reduction of the signal/noise ratio. When developing any ELISA, it is important to test 
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several different blockers for the highest signal/noise ratio in the assay. No single 
blocking agent is ideal for every occasion since each antibody-antigen pair has unique 
characteristics. In this study three different blocking buffers were tested (5%: 
SM/PBS, HAS/PBS and BSA/PBS) at different incubation temperatures (4°C, 37°C), 
and 5% BSA/PBS at 4°C overnight incubation was chosen as a proper blocker. 
The ELISA sensitivity and specificity depend also on the quality of used sera 
which contain the antibodies specific to the coated antigen. Ideally, the positive control 
serum should have a high concentration of antibodies which have to react specifically 
only with the coated antigen. These antibodies should not interact with other reagents 
or even with the solid phase (plastic material). 
This study examined the presence of antibodies against survivin, a widely occur-
ring tumor-associated protein, in sera from lung cancer patients. Using an ELISA tech-
nique, anti-survivin antibody response was detected in lung cancer patients. Specificity 
of survivin recognition was confirmed by preincubation of the sera with soluble sur-
vivin. 
The immune response against cancer cells is complex, involving the interaction of 
many different cell types and cell products, and it is not possible to consider cell-
mediated and antibody-mediated responses in isolation. Functional antitumor immuni-
ty requires a response initiated by potent antigen-presenting cells, such as dendritic 
cells, and the engagement of a variety of effector cells not only cytotoxic T cells, but 
also T-helper cells and B cells, which initiate antibody immunity. However, it is well 
recognised that cytotoxic T lymphocytes (CTL) constitute one of the most important 
effector mechanisms of anti-tumour immunity [133]. CTL are able to perform tumour-
specific recognition via their clonal T cell receptors (TCR) generated via a somatic re-
combination mechanism. Activated CTL can mediate specific destruction of tumour 
cells by the release of lytic components and direct cell–cell interaction. In general, CTL 
are CD8+ and are therefore class I major histocompatibility complex (MHC)-restricted, 
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even though in some instances CD4+ class II MHC restricted T cells have also been 
shown to perform cytolytic activities [134]. 
Over the past decade, it has been demonstrated that cancer is immunogenic, and 
multiple tumor antigens have been identified in cancer patients. It is now possible to 
potentially harness the immune response elicited by cancer growth as a potential di-
agnostic tool. Currently, only a limited number of tumor markers for non-small cell 
lung cancer (NSCLC) are available, and NSCLC heterogeneity makes the identification 
of a single sensitive and specific marker unlikely. Antibodies to tumor-associated pro-
teins may expand the number of available tumor markers for lung cancer, and may be 
used together in a serum profile to enhance sensitivity and specificity. 
Humoral immunity to tumor-associated proteins is receiving renewed attention as 
the appropriate measure of cancer development. This is because antibody responses 
can be generated against non-circulating proteins expressed on the cell surface, irre-
spective of their amount. Antibody measurement is a rather stringent process aiming 
to: a). Increase assay sensitivity, b). Evaluate responses to a panel of proteins rather 
than an individual tumor antigen, c). Evaluate the level of antibody response (titer or 
absolute amount of immunoglobulin), d). Identifying the classes of the reactive anti-
bodies, and finally, e). Determining the most appropriate form of the antigen to be 
used in the assay, for example, “captured” protein, recombinant protein, or even pep-
tides. 
The process of carcinogenesis involves genetic instability, with one estimate of 
over 11000 genomic alterations occurring in a cancer cell [135]. Genetic and epigenet-
ic changes mean that cancer cells can produce novel proteins and over-express pro-
teins normally present at low levels [136]. Multiple peptides are processed from each 
protein, allowing multiple different epitopes or TAAs from tumour-related proteins to 
be presented on the cell surface [19], even at early stage of the disease, autoantibod-
ies to tumor-associated antigens (TAAs) such as HER-2/neu, c-myc, ras, cyclin B1, 
p53, p62, human telomerase reverse transcriptase (hTERT), and survivin have been 
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identified in patients with cancer [106-113]. The detection of autoantibodies may be 
used as an adjunct to more standard serologic tests being evaluated to aid in cancer 
diagnosis, clinical reports of autoantibodies against TAA detected in cancer patients 
with much higher frequency than control donors demonstrate that autoantibodies can 
be raised against both intra- and extracellular proteins, that circulating autoantibodies 
can be found in both early stage as well as preinvasive tumors, and that TAA autoanti-
bodies can be identified in high risk patients who are not yet tumor bearing. All these 
characteristics would be a benefit for a diagnostic assay. However, autoantibodies can 
also be associated with benign disease or even be detected at lower levels in tumor 
bearing individuals than controls. Moreover, measurement of a single autoantibody will 
not provide the adequate sensitivity needed for a diagnostic test. These observations 
underscore the need to fully characterize an autoantibody response across multiple 
populations prior to clinical development. 
The survivin protein regulates both cell division and cell survival and is overex-
pressed in the vast majority of human cancers [68]. Current evidence suggests that 
survivin’s dual function as an anti-apoptotic protein and a chromosomal passenger 
protein makes it a factor favoring cancer progression.  In fact, the gene encoding sur-
vivin is notable for its high degree of tumor-specific expression, ranking among the top 
five most tumor-specific genes in the human genome based on comparisons of the 
number of times survivin transcripts appear in tumors compared with normal cells and 
tissues [137].  In normal cells, survivin is produced only in small amounts and only 
briefly during mitosis. However, in tumors, the survivin protein is continuously present 
at excess levels, suppressing apoptosis and aiding in cell division [68]. 
Consequently, Survivin has emerged as a hot target for cancer therapy, with a 
variety of strategies already articulated for nullifying survivin in tumors, including (a) 
small molecule antagonists that block interactions of survivin with critical partner pro-
teins ; (b) antisense oligonucleotides that reduce survivin expression; (c) ribozyme-
mediated inhibition of survivin expression [138]; and (d) gene therapy using dominant 
negative mutants of survivin that induce cell cycle arrest and apoptosis [139]. Target-
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ing of survivin by RNA interference in a multitude of cancer cell lines leads to an in-
crease in susceptibility to DNA-damage induced programmed cell death, such as by 
chemicals or radiation. 
This indicates that high levels of survivin mediate resistance to chemotherapy 
and radiation [140]. This is clinically significant in that patients harboring tumors ex-
pressing high survivin have poorer clinical outcomes [134]. Current evidence suggests 
that survivin plays an essential role in tumor maintenance by facilitating proliferation, 
angiogenesis, multi-drug resistance and by preventing apoptosis [141]. However, 
whether survivin plays a role in the initiation or establishment of tumors still remains 
unclear. 
This study was undertaken to further explore the immunogenicity of survivin, an 
overexpressed TAA that, due to its nodal role in the survival of cancer cells, is consid-
ered as an ideal target for immunotherapy. It has been demonstrated by several 
groups that survivin is an immunogenic protein eliciting both humoral and cellular im-
mune responses. 
As the success of cancer immunotherapy is dependent on using suitable tumor-
associated antigens (TAAs), an ideal TAA should have several important features. First, 
TAA should induce T cells that recognize tumors but not normal cells. Second, TAA 
should be expressed in tumors from a significant proportion of the patients and in a 
significant proportion of tumor cells. Third, it is important that TAA belongs to mole-
cules, which are obligatory for the survival of tumor cells. Immunization against such 
TAA(s) would overcome tumor escape attributable to antigenic variation because los-
ing the survival-related molecule may result in tumor cell death. At this time, there are 
very few molecules that fit these criteria. Survivin may be one such rare candidate. 
Efforts were made in our laboratory to examine the anti-survivin humoral re-
sponse  under the light of our recent finding that HLA-A restricted peptides of survivin 
do not induce detectable CTL responses [129] as well as bearing in mind that the re-
sults of all three existing studies examining the anti-survivin antibody response in lung 
cancer [117, 121, 122] are inconclusive. In general, the autoantibody responses asso-
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ciated with cancer have attracted limited attention despite the fact that they may pro-
vide useful information about the helper T cell response against TAA. Instead they 
have been extensively studied in the context of been utilised as biomarkers for diagno-
sis [142]. 
In the present study we used the largest in the literature cohort of lung cancer 
patients and controls, and we have shown that autoimmunity against survivin in these 
patients did not differ significantly than that observed in cancer-free individuals. The 
statistically significant difference in the concentration of antibodies, observed in the 
group of NSCLC, obviously represents the effect of extreme values (11.5±15.2 RAU), 
with only three of these values from patients, being above the upper limit of those de-
tected in normal individuals. This finding becomes even more intriguing considering 
that survivin was found to be overexpressed in nearly all NSCLC [46] yet, at the same 
time; this was not accompanied by a detectable anti-survivin CTL response [129]. 
Taken into account all the above, we could consider that either survivin truly appears 
with a low immunogenicity or tolerance against it is easily induced in cancer patients. 
Regarding the latter, it is not amazing for the immune system to recruit tolerizing 
mechanisms in order to protect important molecules, for the survival of the cells, from 
autoreactivity. 
Efforts to correlate the antibody concentration with clinical parameters of the pa-
tients or to identify the characteristics of those appearing with elevated levels at diag-
nosis did not reveal any significance. Taking into account that this study utilized the 
largest cohort of lung cancer patients, this finding is in accordance with those pertain-
ing that, at least when detected alone, anti-survivin antibodies do not present with any 
diagnostic utility [116, 117]. 
Cytotoxic chemotherapy, surgery, and radiotherapy are the major modalities 
used in cancer treatment. Because cytotoxic drugs target dividing cells, the metabolic 
similarities between normal and neoplastic cells lead to low therapeutic indices and 
high toxicity. Bone marrow is particularly susceptible to cytotoxic damage, and the 
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majority of cytotoxic drugs cause neutropenia and, to some degree, lymphopenia, 
thrombocytopenia, and anemia. 
 Radiation therapy and chemotherapy can be applied as an initial treatment (ne-
oadjuvant therapy) with the purpose to shrink the tumor for complete resection of 
borderline respectable tumors (stage III). Alternatively, radiation and chemotherapy 
can be used after surgery for eradication of micrometastases (adjuvant chemotherapy) 
or prevention of local relapse (radiation therapy). 
Different chemotherapeutic agents have been shown to induce different forms of 
cell death, and may have different immunological consequences [143]. Chemotherapy 
may interact to augment immunotherapy by several different mechanisms, including 
increased T cell infiltration  enhanced antigen cross presentation to dendritic cells 
(DCs) and tumour cell sensitization to killing by cytotoxic lymphocytes [144, 145, 
146]. 
Some chemotherapeutic agents are probably more immunogenic than others. For 
example, cyclophosphamide has long been investigated for an ability to deplete Treg 
at doses that relatively spare the rest of the lymphocyte population [147]. Targeted 
therapies also have the potential to interact with the immune system. For example, 
the c-kit tyrosine kinase inhibitor, imatinib, has been reported to activate DCs and 
overcome tumour-induced T cell tolerance [148].  
Agents used to treat hematological malignancies in particular can cause severe 
lymphopenia and profound defects in cell-mediated immunity leading to opportunistic 
infections [149]. 
What has been less clear is the effect of chemotherapy on antitumor immunity. 
Clearly, the destruction of tumor cells by cytotoxic drugs increases the load of tumor 
antigen reaching the draining lymph node. The fact that this increased load fails to 
generate an immune response that controls minimal residual disease is assumed to be 
due to immune suppression. However, this has never been systematically evaluated. 
Most tumors express an array of antigens that could act as targets for their immune-
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mediated destruction, and a number of potential therapies have emerged to exploit 
this [150]. 
Chemo- and radiotherapy kill cancer cells mainly by triggering apoptosis or pro-
grammed cell death [151]. In human cancer cells and tissues, the expression of four 
members of the anti-apoptotic inhibitor of apoptosis (IAP) protein family (XIAP, cIAP1, 
cIAP2 and survivin) has been investigated as a potential factor for chemoresistance, 
based on their ability to inhibit the key molecules of the apoptotic machinery, the 
caspases [152]. As mentioned before survivin is involved in both proliferation and 
apoptosis and its localization is important for its prognostic properties [125, 153]. 
Highly proliferative tumors are more sensitive to chemotherapy suggesting that sur-
vivin expressing tumors might be more sensitive to chemotherapy [154]. Conversely, 
the anti-apoptotic function of survivin would suggest that these tumors would be re-
fractory to cytotoxic treatments, e.g. endocrine therapy. 
Accumulating evidence over the last decade indicates that the host immune sys-
tem contributes to the anti-cancer therapeutic outcome, since cancer cell death elicited 
by radiotherapy and some chemotherapeutic agents seems to be immunogenic [155 , 
156]. Moreover, they induce reduction of the tumor mass directly affecting in this way 
its immunosuppressive properties that can lead to reversal of tumor-induced immune 
tolerance [157]. Platinum-based regimes, like those used in 86% of NSCLC patients in 
this study, have been proved in vitro able to increase the sensitivity of prostate carci-
noma tumor cells to the lethal and lytic effects of tumor-infiltrating lymphocytes  as 
well as the sensitivity of colon carcinoma tumor cells to antigen-specific CTLs [158, 
159]. Our study, however, did not reveal any in vivo correlation between the treat-
ment with cisplatin or carboplatin and the antibody response of the patients. 
Chemotherapy-induced lymphopenia has been regarded as a factor that com-
pounds on the anti-tumor immune response. Treatment with gemcitabine which is a 
nucleoside analogue that is frequently used to treat non-small cell lung cancer, it is 
also active in other malignancies, either alone or in combination with cisplatin, a con-
stituent of the regimens used in 22% NSCLC patients in this study, is known to have a 
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detrimental effect on humoral immune responses [160], without compromising specific 
anti-tumor cellular immunity. Taxanes also given in 46% of our NSCLC patients reduce 
CD19+ cell numbers in animal models [161]. Again, lymphopenia did not prove in our 
study to relate to the antibody response of the patients. 
Notwithstanding the absence of correlations, as discussed above, 19 out of the 
150 examined patients, all with NSCLC appeared with tremendous and constant in-
creases or decreases in their anti-survivin antibody levels, a fact that cannot be over-
looked. Even amongst these patients, no relation was observed either with any treat-
ment regimen or with clinicopathological parameters. To this end, not even the remov-
al of the antigenic stimulus can explain the extreme decreases observed in antibody 
concentration, since 5 out of 7 patients with decrease had not been subjected to sur-
gery. The great increases, however, argue against a low immunogenicity of survivin 
but rather are in support of its strict tolerogenicity that could account for the limited 
anti-survivin antibody response generally. In favor of this are recent data indicating 
that the number and the function of regulatory T cells are negatively affected by 
chemotherapeutic agents, such as taxanes [162, 163]. In such a case, anti-survivin 
autoimmunity might reflect an effectiveness of chemotherapy. In any case, changes of 
anti-survivin antibody levels during cancer treatment seem to be an interesting phe-
nomenon that requires attention and warrants further investigation. It is an intriguing 
question, whether anti-survivin antibodies could also serve as an early predictive 
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5. ΠΕΡΙΛΗΨΗ 
 
Προσδιορισµός της χυµικής ανοσιακής απάντησης έναντι της 
σαρβιβίνης σε ασθενείς µε καρκίνο του πνεύµονα 
SANAA KHALIL 
ΕΡΓΑΣΤΗΡΙΟ ΑΝΟΣΟΛΟΓΙΑΣ-ΙΣΤΟΣΥΜΒΑΤΟΤΗΤΑΣ 
∆ιευθυντής: Καθηγητής Αναστάσιος Ε. Γερµενής 
ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ – ΤΜΗΜΑ ΙΑΤΡΙΚΗΣ 
ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΙΑΣ 
 
Εισαγωγή: Τα µέχρι στιγµής δεδοµένα που αφορούν στην αυτόµατη έναντι της σαρβι-
βίνης χυµική ανοσιακή απάντηση είναι αµφιλεγόµενα. Επιπρόσθετα, παρά το γεγονός 
ότι ο θάνατος των νεοπλασµατικών κυττάρων µετά από ακτινοθεραπεία ή χορήγηση 
χηµειοθεραπευτικών φαρµάκων φαίνεται να είναι ανοσογονικός, λίγα είναι γνωστά για 
την πιθανή επίδραση της αντικαρκινικής θεραπείας στις χυµικές απαντήσεις στον καρκί-
νο. Σκοπός της παρούσας µελέτης ήταν, ο χαρακτηρισµός της αυτόµατης χυµικής ανο-
σιακής απάντησης έναντι του ευρέως εκφραζόµενου αντιγόνου των όγκων σαρβιβίνη, η 
οποία µπορεί να εκλυθεί από τον όγκο, σε ασθενείς µε καρκίνο του πνεύµονα. 
Υλικό και Μέθοδοι: ∆είγµατα ορού από 33 ασθενείς µε πρωτοδιαγνωσθέν µικροκυττα-
ρικό καρκίνο πνεύµονα (SCLC) καθώς και από 117 ασθενείς µε πρωτοδιαγνωσθέν µη 
µικροκυτταρικό καρκίνο πνεύµονα (NSCLC) και δείγµατα ορού από 100 φυσιολογικούς 
µάρτυρες αναλύθηκαν µε ELISA για την ανεύρεση αντισωµάτων έναντι της σαρβιβίνης. 
Αποτελέσµατα:  Ως κατώφλι θετικότητας για την ELISA τέθηκε η µέση τιµή ± 2 SD ( 
mean±2SD) των τιµών των φυσιολογικών µαρτύρων. Σε ποσοστό 7.7% των ασθενών 
µε  NSCLC (OR 3.6, 95% CI: 0.7-17.3), σε κανέναν από τους ασθενείς µε SCLC (OR 
0.6, 95% CI: 0.03-12.6) και στο 2% των φυσιολογικών µαρτύρων βρέθηκαν αυξηµένοι 
τίτλοι αντισωµάτων έναντι της σαρβιβίνης. Από τον προσδιορισµό του τίτλου των αντι-
σωµάτων σε 76 ασθενείς µε NSCLC µετά τη θεραπεία και κατά τη διάρκεια της παρακο-
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λούθησής τους προέκυψαν 12 ασθενείς στους οποίους ο τίτλος αυξήθηκε κατά 2-38 
φορές ενώ σε 7 ο τίτλος µειώθηκε κατά 2-8 φορές. Καµία στατιστικά σηµαντική συσχέ-
τιση δεν αποκαλύφθηκε µεταξύ του τίτλου των αντισωµάτων κατά τη διάγνωση ή των 
µεταβολών του µετά τη θεραπεία, µε οποιαδήποτε κλινική και ιστολογική παράµετρο, 
την ανταπόκριση των ασθενών στη θεραπεία και την επιβίωση τους. 
Συµπέρασµα: Στον καρκίνο του πνεύµονα η σαρβιβίνη φαίνεται να µην προκαλεί 
ισχυρές χυµικές ανοσιακές απαντήσεις. Παρόλα αυτά, είναι πιθανό, µετά τη θεραπεία 
και κατά την παρακολούθηση των ασθενών να εκλύεται ισχυρή χυµική απάντηση µε 
αντισώµατα έναντι της σαρβιβίνης, η κλινική σηµασία των οποίων παραµένει άγνωστη. 
Τα ευρήµατα αυτά σε συνδυασµό µε δεδοµένα που αφορούν στην έκφραση της σαρβι-
βίνης και τις σχετιζόµενες µε αυτή Τ κυτταρολυτικές απαντήσεις στον καρκίνο του 
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